Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This entry refers to an incompletely specified multi-electrolyte intravenous solution containing magnesium chloride, potassium chloride, sodium chloride, sodium gluconate, and a truncated sodium-containing component. In the provided context, the closest fully specified marketed products are balanced crystalloid solutions such as Plasma-Lyte 148, Plasma-Lyte A, and Normosol-R, which typically include sodium acetate in addition to the listed electrolytes. These products are sterile, isotonic **small-molecule electrolyte replacement solutions** administered intravenously to expand extracellular fluid volume and correct electrolyte depletion in settings such as surgery, trauma, burns, shock, and moderate blood loss. The therapeutic effect is produced by replacement of physiologic ions in the extracellular compartment rather than binding to a single discrete molecular target. Because the queried name ends with an incomplete \"sodium\" term and could map to more than one specific marketed formulation, the exact product identity cannot be assigned with confidence from the input alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on magnesium chloride + potassium chloride + sodium chloride + sodium gluconate + sodium.